IFO
CCCC icon

Intrepid Family Office’s C4 Therapeutics CCCC Stock Holding History

Intrepid Family Office’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Buy
60,000
+5,000
+9% +$11.8K 0.13% 35
2025
Q4 		$105K Sell
55,000
-15,000
-21% -$35.5K 0.09% 34
2025
Q3 		$155K Buy
70,000
+30,000
+75% +$72K 0.13% 34
2025
Q2 		$57.2K Hold
40,000
– – 0.05% 38
2025
Q1 		$64K Hold
40,000
– – 0.09% 30
2024
Q4 		$144K Buy
+40,000
New +$199K 0.15% 32

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Intrepid Family Office's CCCC Position: Q1 2026 in Review

Intrepid Family Office increased its C4 Therapeutics (CCCC) stake by 9.1% in Q1 2026, buying an estimated $11.8K and bringing the position to 60,000 shares worth $158K. The position accounts for 0.13% of the portfolio, ranked #35.

Intrepid Family Office first reported a position in CCCC in Q4 2024 and has held it in 6 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Intrepid Family Office held 60,000 shares of C4 Therapeutics worth $158K as of Q1 2026.
  • Intrepid Family Office bought 5,000 C4 Therapeutics shares in Q1 2026, an estimated $11.8K.
  • C4 Therapeutics made up 0.13% of Intrepid Family Office's portfolio in Q1 2026, its #35 holding.
  • Intrepid Family Office first reported a position in C4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Intrepid Family Office's 13F filing for Q1 2026, filed 15 May 2026.